Stevanato Group, a global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced to have secured EUR 200 million in financing through agreements with BNL BNP Paribas, Cassa Depositi e Prestiti (CDP) and Banco BPM. These fundings are intended to support the Company’s ongoing capital expenditure projects in Cisterna di Latina, Italy, and Fishers, Indiana, USA.
The financing agreements bolster Stevanato Group’s capacity expansion efforts and the scaling of commercial production to support customers’ growing biologics programs. CDP has committed EUR 50 million to enhance the production of pre-filled syringes and set-up future capacity for ready-to-use (RTU) cartridges at Stevanato Group’s Italian plant in Cisterna di Latina. Additionally, BNL BNP Paribas has provided EUR 100 million, and Banco BPM has contributed EUR 50 million, both aimed at scaling pre-filled syringe production at the company’s facilities in North America and Italy, as well as completing the ongoing construction for device manufacturing in Fishers.
“These agreements are an important element to Stevanato Group’s financial strategy, allowing us to capitalize on robust customer demand and support the Company’s long-term growth objectives,” sais Marco Dal Lago, Chief Financial Officer of Stevanato Group. “We are committed to supporting our customers’ biopharmaceutical programs with our unique value proposition of offering integrated solutions across the pharmaceutical value chain, helping to enable our customers to meet and exceed their program objectives.”
BNL BNP Paribas and Cassa Depositi e Prestiti have renewed their support for Stevanato Group to achieve long-term organic growth objectives in its key end-markets.